BMY Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Bristol-Myers Squibb Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$59.94 |
52 Week High | US$61.08 |
52 Week Low | US$39.35 |
Beta | 0.44 |
11 Month Change | 10.35% |
3 Month Change | 18.65% |
1 Year Change | 19.93% |
33 Year Change | 5.47% |
5 Year Change | -2.19% |
Change since IPO | 2,705.24% |
Recent News & Updates
Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)
Nov 275 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Nov 25Recent updates
Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)
Nov 275 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
Nov 25Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Oct 28Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Oct 06Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Sep 27Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows
Sep 06Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues
Aug 15Bristol-Myers Squibb: A Potential Comeback In Healthcare
Aug 06Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Jul 27Bristol Myers Squibb: The More It Drops, The More I Buy
Jul 16Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?
Jun 13Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
Jun 09Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
Jun 03Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
May 23Bristol-Myers Squibb: A Lost Decade?
May 03Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S
Apr 29Is Bristol Myers Squibb A Buy At These Bottom Levels?
Apr 22Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Apr 12Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
Apr 02Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 21Bristol-Myers Squibb Is Not A Buy For Me
Mar 19Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Mar 07Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 07Shareholder Returns
BMY | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.0% | 1.9% | 0.7% |
1Y | 19.9% | 12.1% | 32.2% |
Return vs Industry: BMY exceeded the US Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: BMY underperformed the US Market which returned 32.2% over the past year.
Price Volatility
BMY volatility | |
---|---|
BMY Average Weekly Movement | 4.4% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
BMY fundamental statistics | |
---|---|
Market cap | US$120.11b |
Earnings (TTM) | -US$7.26b |
Revenue (TTM) | US$47.44b |
2.6x
P/S Ratio-16.7x
P/E RatioIs BMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BMY income statement (TTM) | |
---|---|
Revenue | US$47.44b |
Cost of Revenue | US$11.44b |
Gross Profit | US$35.99b |
Other Expenses | US$43.25b |
Earnings | -US$7.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
Earnings per share (EPS) | -3.58 |
Gross Margin | 75.87% |
Net Profit Margin | -15.30% |
Debt/Equity Ratio | 289.5% |
How did BMY perform over the long term?
See historical performance and comparison